GlassScriptPhysician profile
Lisa A June
NPI 1689749798
$27,240.73
in general payments reported to CMS, 2019-2025
35 companies · $3,274 in 2025
The $3,274 reported for 2025 was more than what 79% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,152 · 2020: $3,181 · 2021: $4,021 · 2022: $3,777 · 2023: $4,378 · 2024: $4,458 · 2025: $3,274.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $249.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,860.86 |
| Education | $248.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $4,151.44 | 2019-2025 | Enbrel, Otezla, Otezla |
| Abbvie INC. | $3,746.76 | 2019-2025 | |
| Ucb, INC. | $3,577.58 | 2019-2025 | Cimzia, Bimzelx |
| Janssen Biotech, INC. | $2,948.72 | 2019-2025 | Tremfya, Simponi Aria |
| Pfizer INC. | $2,142.63 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,927.10 | 2021-2025 | Saphnelo, Evusheld |
| Novartis Pharmaceuticals Corporation | $1,449.08 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,444.00 | 2019-2025 | Orencia |
| Glaxosmithkline, LLC. | $1,279.28 | 2019-2025 | Benlysta, Nucala |
| Lilly USA, LLC | $1,026.57 | 2019-2024 | Taltz |
| Radius Health, INC. | $596.40 | 2019-2025 | Tymlos |
| Regeneron Healthcare Solutions, INC. | $493.44 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $412.04 | 2019-2025 | Ofev, Cyltezo |
| Mallinckrodt Hospital Products INC. | $303.19 | 2022-2024 | Acthar |
| Genentech USA, INC. | $228.09 | 2019-2025 | Actemra, Gazyva |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $221.44 | 2020-2025 | |
| Celgene Corporation | $207.87 | 2019-2021 | |
| Octapharma USA, INC. | $193.73 | 2022-2025 | Octagam Immune Globulin (Human), Panzyga |
| Organon LLC | $171.29 | 2023-2025 | Hadlima, Renflexis |
| Fresenius Kabi USA, LLC | $139.75 | 2023-2025 | Idacio, Tyenne, Stimufend |
| Aurinia Pharma U.S., INC. | $99.92 | 2024-2025 | Lupkynis |
| Sandoz INC. | $75.68 | 2023-2024 | Hyrimoz |
| Sobi, INC | $61.29 | 2019-2023 | |
| Medexus Pharma, INC. | $54.24 | 2019 | |
| Horizon Therapeutics Plc | $52.80 | 2020-2021 | |
| Ultragenyx Pharmaceutical INC. | $46.17 | 2024 | Crysvita |
| Oxford Immunotec USA INC | $42.95 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $29.36 | 2020 | |
| Qiagen, LLC | $24.08 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $18.72 | 2024 | Simlandi |
| United Therapeutics Corporation | $18.17 | 2024 | Tyvaso |
| Arcutis Biotherapeutics, INC. | $17.57 | 2023 | |
| Alexion Pharmaceuticals, INC. | $14.77 | 2019 | |
| Hikma Pharmaceuticals USA | $13.12 | 2020 | |
| Avion Pharmaceuticals | $11.49 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa June listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.